Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)

Win Min Oo; David J Hunter

doi:10.1177/1759720X221090297

Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)

Ther Adv Musculoskelet Dis. 2022 May 20:14:1759720X221090297. doi: 10.1177/1759720X221090297. eCollection 2022.

Authors

Win Min Oo¹, David J Hunter²

Affiliations

¹ Rheumatology Department, Royal North Shore Hospital, and Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
² Rheumatology Department, Royal North Shore Hospital, and Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2065, Australia.

Abstract

In spite of a major public health burden with increasing prevalence, current osteoarthritis (OA) management is largely palliative with an unmet need for effective treatment. Both industry and academic researchers have invested a vast amount of time and financial expense to discover the first diseasing-modifying osteoarthritis drugs (DMOADs), with no regulatory success so far. In this narrative review, we discuss repurposed drugs as well as investigational agents which have progressed into phase II and III clinical trials based on three principal endotypes: bone-driven, synovitis-driven and cartilage-driven. Then, we will briefly describe the recent failures and lessons learned, promising findings from predefined post hoc analyses and insights gained, novel methodologies to enhance future success and steps underway to overcome regulatory hurdles.

Keywords: DMOADs; disease-modifying drugs; endotype; intra-articular therapy; osteoarthritis.

Publication types

Address
Review